Cleveland BioLabs, Inc.  

(Public, NASDAQ:CBLI)   Watch this stock  
Find more results for CBLI
3.59
+0.12 (3.46%)
Feb 9 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.52 - 3.70
52 week 1.84 - 7.24
Open 3.57
Vol / Avg. 9,967.00/27,858.00
Mkt cap 39.20M
P/E 2.60
Div/yield     -
EPS 1.38
Shares 10.73M
Beta 1.44
Inst. own 11%
Feb 22, 2016
Q4 2015 Cleveland Biolabs Inc Earnings Release (Estimated) Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -641.18% 0.96%
Operating margin -561.68% -5.82%
EBITD margin - -384.16%
Return on average assets -81.87% 0.29%
Return on average equity -3825.31% -
Employees 33 -
CDP Score - -

Address

73 High St
BUFFALO, NY 14203-1149
United States - Map
+1-716-8496810 (Phone)
+1-716-8496820 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company’s programs are focused on the implementation of novel pharmacological approaches to control cell death. Its proprietary drug candidates act through mechanisms and targets to kill cancer and protect healthy cells. The Company’s lead product candidates include Entolimod, which is designed for biodefense indication and as an oncology drug, and Curaxin CBL0137, a lead oncology product candidate. The Company’s products include Entolimod (CBLB502) Biodefense, Entolimod (CBLB502) Oncology, CBLB612, CBLC102 and CBLC137, Revercom, Mobilan, Arkil, Antimycon and Xenomycins. The Company’s subsidiaries include Incuron, LLC, which develops product candidates CBL0102 and CBL0137 for oncology indications; and Panacela, which develops new preclinical product candidates, primarily focused in oncology.

Officers and directors

Langdon L. Miller M.D. President and Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Yakov N. Kogan Ph.D. Chief Executive Officer, Director
Age: 41
Bio & Compensation  - Reuters
C. Neil Lyons CPA Chief Financial Officer
Age: 58
Bio & Compensation  - Reuters
Andrei V. Gudkov Ph.D. Chief Scientific Officer, Director
Age: 58
Bio & Compensation  - Reuters
Anna Evdokimova Director
Bio & Compensation  - Reuters
Konstantin Gorshkov Director
Bio & Compensation  - Reuters
Natalia Khudyk Director
Bio & Compensation  - Reuters
Yulia Lebedina Director
Age: 36
Bio & Compensation  - Reuters
Tatiana Levina Director
Bio & Compensation  - Reuters